$SI

SHOULDER INNOVATIONS, INC.

Shoulder Innovations, Inc. is a commercial-stage medical technology company focused exclusively on shoulder surgical care. It develops and sells implant systems for anatomic and reverse total shoulder arthroplasty, including its InSet Glenoid technology and a range of humeral stem options. Its product ecosystem also includes ProVoyance, a preoperative planning technology that uses AI and machine learning to create 3D renderings from CT imaging, a two-tray instrument system, specialized support for surgeons, and surgeon education and collaboration. Shoulder Innovations makes money by selling its shoulder implant systems and related products. It supports surgeons and physician practices with planning technology, procedural assistance, training, and digital tools, including patient acquisition and outcomes resources. Its commercial organization includes a dedicated team and independent distributors. The company is headquartered in Grand Rapids, Michigan.

1
0
0

No SEC Form 4 filings for $SI in the last 30 days.

See all $SI insider activity →
Low

Shoulder Innovations Doubles Customer Growth, Sets Sights on Surgical Robotics

Shoulder Innovations (NYSE:SI) reported doubling customer growth and highlighted its InSet Glenoid implant's 100% survivorship rate. The company also discussed its integrated surgical system, AI planning tool, and plans to file a 510(k) submission for a robotic system in 2027. It estimates the U.S. market for shoulder procedures at $5 billion.

What Shoulder Innovations (SI) Said on Its Q3 Earnings Call

Shoulder Innovations (SI) reported Q3 expenses rising due to hiring and R&D. Cash reserves were $92.3M, with improved burn rate. Surgeon growth and implant volume increased 34% YoY. New products and partnerships were announced, with FDA submissions planned for 2027. Management expects cash flow break-even with current reserves.

Shoulder Innovations reports Q3 results (NYSE:SI)

Shoulder Innovations reported Q3 revenue of $16.2M, up 37.8% year-over-year, exceeding estimates by $0.74M. Adjusted EBITDA loss narrowed to $5.5M from $7.5M in the same period last year. The company expects net revenue growth for the full year.

SI sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning SI (SHOULDER INNOVATIONS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent SI coverage spans earnings, technology and financial news.

What's driving SI

AlphAI scores every news story that mentions SI with an AI model for sentiment and relevance, and aggregates insider trades from SHOULDER INNOVATIONS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SI

Score

What Shoulder Innovations (SI) Said on Its Q3 Earnings Call

Shoulder Innovations (SI) reported Q3 expenses rising due to hiring and R&D. Cash reserves were $92.3M, with improved burn rate. Surgeon growth and implant volume increased 34% YoY. New products and partnerships were announced, with FDA submissions planned for 2027. Management expects cash flow break-even with current reserves.

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

Related tickers